Drug approvals in 2021 continued at a pace consistent with prior years, but a large backlog of inspections is slowing some approvals. Cell and gene therapies investment is growing rapidly and promises substantial revenue growth in the coming years. Read about other sectors 2021 FDA approvals ... READ MORE >
5 things to know in life sciences: Week of Jan. 31, 2022
This week, we highlight a breakthrough tubeless insulin pump which received Food and Drug Administration clearance. We also look at a telehealth pharmacy booming during the pandemic, potential breakthroughs in neurovascular research, the disparity of Asian scientists’ contributions and recognition in ... READ MORE >
5 things to know in life sciences: Week of Jan. 24
This week we look at the ethical challenges facing neuroscientists as they recruit patients for clinical research. We also look at a ride share company entering the health care space and what it may mean for clinical trial recruitment, CBD as a prevention measure for COVID-19, deltacron and ... READ MORE >
5 things to know in life sciences: Week of Jan. 17, 2022
This week, we look at antimicrobial-resistant diseases, their toll on health systems globally and the need for new treatments. We also feature the continued delays in Food and Drug Administration inspections, the demand for decentralized trials, as well as medtech's initial public offerings and their ... READ MORE >
5 things to know in life sciences: Week of Jan. 10
This week we highlight a flood of studies and approvals with a focus on leveraging new technologies, data and gene sequencing to increase patient care. While the life sciences industry has always been on the forefront of innovation, we are now seeing the various components of the ecosystem come together ... READ MORE >
5 things to know in life sciences: Week of Jan. 3
This week we explore a partnership between a large biopharma and a machine learning startup. In addition, we look at a non-commercial approach to address the global COVID-19 vaccine shortage, a major mRNA-focused acquisition, a temporary pause on factory inspections, and finally, 55 new drug approvals in ... READ MORE >
Five things to know in life sciences: Week of Dec. 13
This week, Pfizer announced another major investment in manufacturing capacity in the United States. Its investment in a new facility is focused on tackling the unique challenges in manufacturing gene therapies. We also look at the possibility of replacing glasses with eye drops, crowdsourcing cancer ... READ MORE >
Five things to know in life sciences: Week of Dec. 6
This week a new investment fund is starting that is focused on the modest goal of extending human life. We also look at new leadless pacemakers, using illustrated stories to make the complexity of clinical trials easier for patients to understand, and studying the common cold as a window into future ... READ MORE >
Five things we don’t know about omicron: Week of November 29
This week it is unavoidable not to mention omicron and so we’ve decided to dedicate our issue of “5 things in life sciences” to this very topic. In a twist from all of the articles about “what we know” about the new variant, however, we thought the community would be better served to talk about what we ... READ MORE >
5 things to know in life sciences: Week of November 15
This week we look at the Food and Drug Administration’s approval of a virtual reality system to treat chronic lower back pain. We also explore a new round of anti-amyloid drugs seeking FDA approval to treat Alzheimer’s disease, a sustainable method to manufacture pharmaceuticals, another deal to license ... READ MORE >